MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing pro-inflammatory macrophage activation.
Myocardial infarction (MI)
connexin 43 (Cx43)
microRNA-155 (miR-55)
ventricular arrhythmias
Journal
Cardiovascular diagnosis and therapy
ISSN: 2223-3652
Titre abrégé: Cardiovasc Diagn Ther
Pays: China
ID NLM: 101601613
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
01
12
2021
accepted:
01
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
ppublish
Résumé
Degradation of pro-inflammatory macrophage-mediated connexin 43 (Cx43) plays an important role in post-myocardial infarction (MI) arrhythmogenesis, microRNA (miR)-155 produced by macrophages has been shown to mediate post-MI effects. We hypothesized that miR-155 inhibition attenuated MI-induced Cx43 degradation by reducing pro-inflammatory macrophage activation. MI was induced by permanent ligation of the left anterior descending coronary artery in male C57BL/6 mice. Lipopolysaccharide (LPS)-stimulated mice bone marrow-derived macrophages (BMDMs) and hypoxia-induced neonatal rat cardiomyocytes (NRCMs) were used The expression levels of miR-155, interleukin-1 beta (IL-1β), and matrix metalloproteinase (MMP)7 were higher in MI mice and LPS-treated BMDMs than in the sham/control groups, treatment with a miR-155 antagomir reversed these effects. Moreover, miR-155 inhibition reduced ventricular arrhythmias incidence and improved cardiac function in MI mice. Cx43 expression was decreased in MI mice and hypoxia-exposed NRCMs, and hypoxia-induced Cx43 degradation in NRCMs was reduced by application of conditioned medium from LPS-induced BMDMs treated with the miR-155 antagomir, but increased by conditioned medium from BMDMs treated with a miR-155 agomir. Importantly, NRCMs cultured in conditioned medium from LPS-induced BMDMs transfected with small interfering RNA against IL-1β and MMP7 showed decreased hypoxia-mediated Cx43 degradation, and this effect also was diminished by BMDM treatment with the miR-155 agomir. Additionally, siRNA-mediated suppressor of cytokine signaling 1 (SOCS1) knockdown in LPS-induced BMDMs promoted Cx43 degradation in hypoxia-exposed NRCMs, and the effect was reduced by the miR-155 inhibition. MiR-155 inhibition attenuated post-MI Cx43 degradation by reducing macrophage-mediated IL-1β and MMP7 expression through the SOCS1/nuclear factor-κB pathway.
Sections du résumé
Background
UNASSIGNED
Degradation of pro-inflammatory macrophage-mediated connexin 43 (Cx43) plays an important role in post-myocardial infarction (MI) arrhythmogenesis, microRNA (miR)-155 produced by macrophages has been shown to mediate post-MI effects. We hypothesized that miR-155 inhibition attenuated MI-induced Cx43 degradation by reducing pro-inflammatory macrophage activation.
Methods
UNASSIGNED
MI was induced by permanent ligation of the left anterior descending coronary artery in male C57BL/6 mice. Lipopolysaccharide (LPS)-stimulated mice bone marrow-derived macrophages (BMDMs) and hypoxia-induced neonatal rat cardiomyocytes (NRCMs) were used
Results
UNASSIGNED
The expression levels of miR-155, interleukin-1 beta (IL-1β), and matrix metalloproteinase (MMP)7 were higher in MI mice and LPS-treated BMDMs than in the sham/control groups, treatment with a miR-155 antagomir reversed these effects. Moreover, miR-155 inhibition reduced ventricular arrhythmias incidence and improved cardiac function in MI mice. Cx43 expression was decreased in MI mice and hypoxia-exposed NRCMs, and hypoxia-induced Cx43 degradation in NRCMs was reduced by application of conditioned medium from LPS-induced BMDMs treated with the miR-155 antagomir, but increased by conditioned medium from BMDMs treated with a miR-155 agomir. Importantly, NRCMs cultured in conditioned medium from LPS-induced BMDMs transfected with small interfering RNA against IL-1β and MMP7 showed decreased hypoxia-mediated Cx43 degradation, and this effect also was diminished by BMDM treatment with the miR-155 agomir. Additionally, siRNA-mediated suppressor of cytokine signaling 1 (SOCS1) knockdown in LPS-induced BMDMs promoted Cx43 degradation in hypoxia-exposed NRCMs, and the effect was reduced by the miR-155 inhibition.
Conclusions
UNASSIGNED
MiR-155 inhibition attenuated post-MI Cx43 degradation by reducing macrophage-mediated IL-1β and MMP7 expression through the SOCS1/nuclear factor-κB pathway.
Identifiants
pubmed: 35800355
doi: 10.21037/cdt-21-743
pii: cdt-12-03-325
pmc: PMC9253173
doi:
Types de publication
Journal Article
Langues
eng
Pagination
325-339Commentaires et corrections
Type : ErratumIn
Informations de copyright
2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-21-743/coif). All authors report that this work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant Nos. LHGJ20200072, LHGJ20200071 and LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030). The authors have no other conflicts of interest to declare.
Références
Sci Rep. 2015 Sep 08;5:13807
pubmed: 26348407
Inflammopharmacology. 2020 Apr;28(2):525-540
pubmed: 31686273
Eur J Heart Fail. 2016 Aug;18(8):1000-8
pubmed: 27072074
Heart Rhythm. 2015 Jan;12(1):169-78
pubmed: 25304682
Nat Commun. 2021 Mar 2;12(1):1394
pubmed: 33654093
Nature. 2020 Dec;588(7838):466-472
pubmed: 32971526
Atherosclerosis. 2004 May;174(1):93-8
pubmed: 15135256
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
J Clin Invest. 2020 Sep 1;130(9):4858-4870
pubmed: 32525845
J Mol Cell Cardiol. 2012 Dec;53(6):880-90
pubmed: 23079193
J Inflamm Res. 2021 Apr 07;14:1297-1311
pubmed: 33854357
Basic Res Cardiol. 2013 Jul;108(4):357
pubmed: 23740215
Circulation. 2013 Sep 24;128(13):1420-32
pubmed: 23956210
Cell. 2017 Apr 20;169(3):510-522.e20
pubmed: 28431249
Pharmacol Ther. 2015 Sep;153:90-106
pubmed: 26073311
Eur J Pharmacol. 2015 Dec 5;768:71-6
pubmed: 26499977
Life Sci Alliance. 2020 Oct 23;3(12):
pubmed: 33097557
Eur Heart J. 2021 Oct 7;42(38):3965-3975
pubmed: 33693589
Clin Sci (Lond). 2014 Jun;126(11):795-803
pubmed: 24283299
Cardiovasc Res. 2020 May 1;116(6):1101-1112
pubmed: 31841135
Biomed Res Int. 2016;2016:9869208
pubmed: 28018919
Basic Res Cardiol. 2021 Feb 9;116(1):10
pubmed: 33564961
Mol Reprod Dev. 2005 Jul;71(3):275-83
pubmed: 15803458
Cardiovasc Res. 2008 Oct 1;80(1):9-19
pubmed: 18519446
Eur J Pharmacol. 2019 Aug 15;857:172449
pubmed: 31207208
J Cardiovasc Pharmacol Ther. 2016 Nov;21(6):526-535
pubmed: 26821570
J Cell Mol Med. 2017 Nov;21(11):2695-2710
pubmed: 28470940
J Clin Invest. 2012 Nov;122(11):4190-202
pubmed: 23041630
Circulation. 1997 Feb 18;95(4):988-96
pubmed: 9054762
J Am Coll Cardiol. 2016 May 3;67(17):2050-60
pubmed: 27126533
Circ Res. 2014 May 9;114(10):1585-95
pubmed: 24657879
Circ Res. 2012 Aug 3;111(4):415-25
pubmed: 22715471
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1421-1427
pubmed: 30794866
Heart Rhythm. 2017 May;14(5):727-736
pubmed: 28111350
J Am Coll Cardiol. 2010 Apr 13;55(15):1629-38
pubmed: 20378083
Circ Res. 2017 Jun 23;121(1):56-70
pubmed: 28404615
PLoS One. 2012;7(11):e46551
pubmed: 23189122
Circulation. 2015 Nov 17;132(20):1880-90
pubmed: 26358260
J Mol Cell Cardiol. 2021 Jun;155:58-65
pubmed: 33636223
Clin Sci (Lond). 1996 Jun;90(6):447-52
pubmed: 8697713
Mol Ther. 2017 Jan 4;25(1):192-204
pubmed: 28129114
Circulation. 2006 Jun 27;113(25):2919-28
pubmed: 16769909
J Leukoc Biol. 2007 Aug;82(2):265-71
pubmed: 17470533
BMC Cancer. 2019 Jul 12;19(1):685
pubmed: 31299935
Immunopharmacol Immunotoxicol. 2021 Aug;43(4):487-494
pubmed: 34227443
Eur J Pharmacol. 2019 May 15;851:122-132
pubmed: 30721702
J Cardiovasc Pharmacol Ther. 2016 Jul;21(4):423-35
pubmed: 26589288
Redox Biol. 2019 Jun;24:101186
pubmed: 30978539
Redox Biol. 2020 Oct;37:101747
pubmed: 33045622
Mol Ther Nucleic Acids. 2016 Oct 11;5(10):e374
pubmed: 27727247
Circ Res. 2001 Feb 16;88(3):333-9
pubmed: 11179202
J Intern Med. 2012 Sep;272(3):267-76
pubmed: 22243053
J Mol Cell Cardiol. 2021 Jun;155:25-35
pubmed: 33549680
J Biol Chem. 2001 Jul 27;276(30):28261-7
pubmed: 11375993